Celsion Corp
LSE:0HUZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Celsion Corp
LSE:0HUZ
|
US |
|
JSR Corp
TSE:4185
|
JP |
|
Garb Oil & Power Corp
OTC:GARB
|
US |
|
HuBei XingFa Chemical Group Co Ltd
SSE:600141
|
CN |
|
N
|
Nippon Rad Inc
TSE:4736
|
JP |
|
PSI Software AG
XETRA:PSAN
|
DE |
|
HT Media Ltd
NSE:HTMEDIA
|
IN |
|
Doright Co Ltd
SZSE:300950
|
CN |
|
Hyliion Holdings Corp
NYSE:HYLN
|
US |
|
P
|
Prince Pipes and Fittings Ltd
BSE:542907
|
IN |
|
Precipio Inc
NASDAQ:PRPO
|
US |
Celsion Corp
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
